Acetazolamide is used to treat glaucoma, a group of eye diseases that can cause vision loss and blindness by damaging a optic nerve nerve. Acetazolamide decreases the pressure in the eye.
Zydus Lifesciences has gets final approval for manufacturing and distribution of Acetazolamide Tablets with strength 125 mg and 250 mg from the United States Food and Drug Administration (USFDA) under the brand name Diamox Tablets.
Acetazolamide is used for the treatment of glaucoma, a eye diseases in which increased pressure on nerve in the back of your eye called the optic nerve and can lead to to gradual nerve damage that can cause vision loss and blindness. Acetazolamide decreases the pressure in the eye. Acetazolamide Tablets have annual sales of 16 million dollars in US last year.
Acetazolamide is also used with symptoms like headache, fatigues, shortness of breath, mountain sickness, dizziness, drowsiness, reduce edema and also in certain types of epilepsy (seizures).
Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil. Zydus’ global business has a strong presence in the regulated markets of the US, Europe, Latin America and South Africa. Zydus Lifesciences group has now more than 358 products approvals and submitted more than 440 Abbreviated New Drug Application (ANDA).